A retrospective study of persons >60 years treated with either anti-TNF or vedolizumab found that more persons with Crohn’s disease (but not ulcerative colitis) on anti-TNF therapy were in remission at three months, though there was no difference between anti-TNF therapy and vedolizumab in either Crohn’s disease or ulcerative colitis at six and 12 months (28). The gene discussed is TNF; the disease is ulcerative colitis.